Abstracts tagged "Abatacept"

Abstract Number: 1648 • 2015 ACR/ARHP Annual Meeting
The Balance of Foxp3/Ror-Gammat Expression Is Altered By Tocilizumab and By Abatacept in Patients with Rheumatoid Arthritis
Yoshifumi Tada¹, Syuichi Koarada², Nobuyuki Ono², Akihito Maruyama², Satoko Tashiro², Yukiko Tokuda², Yukihide Ono², Yoshinobu Nakao² and Akihide Ohta³, ¹Department of Internal Medicine, Division of Rheumatology, Saga University, Saga, Japan, ²Rheumatology, Saga University, Saga, Japan, ³Department of Adult and Gerontological Nursing, Saga University School of Medicine, Saga, Japan
Background/Purpose: It has been shown that the balance between Th17 cells and regulatory T (Treg) cells plays an important role for the development of autoimmune…
Abstract Number: 449 • 2015 ACR/ARHP Annual Meeting
Change from SC to IV Abatacept and Back in Patients with Rheumatoid Arthritis As Simulation of a Vacation: A Prospective Phase IV, Open Label Trial (A-BREAK)
Ruediger Mueller¹, Michael Gengenbacher², Symi richter³, Jean Dudler⁴, Burkhard Moeller⁵ and Johannes von Kempis⁶, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Bethesdaspital, Basel, Switzerland, ³Bethsdaspital, Basel, Switzerland, ⁴Kantonsspital Fribourg, Fribourg, Switzerland, ⁵Rheumatology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Holiday seasons can present a major problem to RA patients treated with weekly subcutaneous biologics, including subcutaneous (SC) abatacept. Therefore an evaluation of the…
Abstract Number: 2150 • 2015 ACR/ARHP Annual Meeting
Treatment with Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis
Matthieu Ponsoye¹, Camelia Frantz², Nadira Ruzehaji³, Muriel Elhai⁴, Barbara Ruiz¹, Anne Cauvet¹, Yannick Allanore⁵ and Jerome Avouac⁴, ¹INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ²Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ³INSERM U1016, Paris Descartes University, Paris, France, ⁴Rheumatology A department and INSERM U1016, Paris Descartes University, Cochin Hospital, Paris, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, And Eular Scleroderma Trials And Research (EUSTAR) Board, Paris, France
Background/Purpose: Early stages of systemic sclerosis (SSc) are characterized by inflammatory skin infiltrates mainly composed of activated T cells. Cytotoxic T-lymphocyte associated molecule-4 (CTLA-4) is…
Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
Abstract Number: 2361 • 2015 ACR/ARHP Annual Meeting
Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: a Randomized, Treatment Delayed-Start Trial
Ingrid E. Lundberg¹, Anna Tjärnlund², Quan Tang³, Cecilia Wick², Maryam Dastmalchi⁴, Herman F Mann⁵, Jana Tomasová Studýnková⁵, Radka Chura⁶, Nicola J. Gullick⁷, Rosaria Salerno⁷, Eva Lindroos^3,8, Patrick Gordon⁶ and Jiri Vencovsky⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Solna, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ⁷Rheumatology, Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ⁸Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden
Background/Purpose: The aim of the study was to assess the effects of abatacept, a T cell blocking agent, on disease activity and on muscle biopsy…
Abstract Number: 456 • 2015 ACR/ARHP Annual Meeting
Disease and Treatment Characteristics That Might Influence Long-Term Retention with Biologics in the Real-World Clinical Setting: Experience from the Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Institut de Rhumatologie, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Disease and Treatment Characteristics that Might Influence Long-term Retention with Biologics in the Real-world Clinical Setting: Experience from the Rhumadata Clinical Database and Registry Background/Purpose:…
Abstract Number: 2651 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Impact of Disease-Modifying Antirheumatic Drugs on Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice
E Alemao¹, KK Gandhi¹, C Iannaccone², M Frits², JS Coblyn², N Shadick² and Michael Weinblatt², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Testing for anti-citrullinated peptide antibodies (ACPA) is included in the 2010 ACR classification criteria for RA. ACPA concentration, beyond ACPA positivity, is indicative of…
Abstract Number: 1515 • 2014 ACR/ARHP Annual Meeting
The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate
T W J Huizinga¹, S E Connolly², Daniel E. Furst³, Vivian P. Bykerk⁴, Gerd Burmester⁵, B G Combe⁶, C S Karyekar², D Wong², L Trouw¹, R E M Toes⁷ and P Emery⁸, ¹Leiden University Medical Center, Leiden, Netherlands, ²Bristol-Myers Squibb, Princeton, NJ, ³University of California at Los Angeles, Los Angeles, CA, ⁴Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Charité – University Medicine Berlin, Berlin, Germany, ⁶Montpellier University Hospital, Montpellier, France, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸University of Leeds, Leeds, United Kingdom
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a marker of RA and may contribute to disease progression.1,2 ACPA analysis in patients offers the opportunity to estimate…
Abstract Number: 1520 • 2014 ACR/ARHP Annual Meeting
Gene Expression Analyses of Abatacept- and Adalimumab-Treated Patients from the Ample Trial
S Bandyopadhyay¹, M Maldonado¹, M Schiff², ME Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The distinct mechanisms of action (MoA) of abatacept (ABA) and adalimumab (ADA) are expected to manifest in different transcriptional profiles in RA patients (pts).…
Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting
Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Anders Gülfe¹, Johan A. Karlsson² and Lars-Erik Kristensen³, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ³Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…
Abstract Number: 504 • 2014 ACR/ARHP Annual Meeting
Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries
Axel Finckh¹, David Neto², M. Victoria Hernández³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhao⁶, K Pavelka⁷, Carl Turesson⁸, Xavier Mariette⁹, Merete Lund Hetland¹⁰ and Jacques Gottenberg¹¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²University of Geneva, Geneva, Switzerland, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Reumatologia Universita e Policlinico di Bari, Bari, Italy, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁶Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, ⁷Institute of Rheumatology, Prague, Czech Republic, ⁸Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ¹⁰DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose Some observations have suggested that the effectiveness of abatacept (ABA) may be decreased in rheumatoid arthritis (RA) patients (pts) who previously failed rituximab (RTX).(1)…
Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting
Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting
Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis
A Obry^1,2, P Cosette², T Lequerré^1,3, Maria-Antonietta d'Agostino⁴, C Gaillez⁵, M Le Bars⁶ and O Vittecoq^1,3, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, ³Department of Rheumatology, Rouen University Hospital, Rouen, France, ⁴AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…
Abstract Number: 516 • 2014 ACR/ARHP Annual Meeting
The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study
Shinya Hirabara¹, Toshihisa Kojima², Nobunori Takahashi², Yuji Hirano¹, Atsushi Kaneko³, Daihei Kida⁴, Yasuhide Kanayama⁵ and Naoki Ishiguro², ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan, ⁵Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Background/Purpose: Roughly 10-30% of rheumatoid arthritis (RA) patients reportedly develop pulmonary complications. These patients are at increased risk of MTX or biologics-induced damage, which often…
Abstract Number: 2504 • 2014 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT), a selective co-stimulation modulator, is the first in a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].